Abbott Laboratories (ABT) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$102.03

Open

$101.89

Day range

$101.50 – $103.30

Volume

5.2M

About Abbott Laboratories

Latest ABT news

• In the News: Muer Yang on Private Equity’s Medical Device Push
  Private Equity · Sep 8, 2026

  Muer Yang, a prominent figure in the private equity sector, has recently highlighted the growing interest of private equity firms in the medical device industry. This trend is largely driven by the sector's potential for high returns, bolstered by an aging population and increasing demand for innovative healthcare solutions. Yang noted that private equity investments in medical devices have surged, as firms seek to capitalize on advancements in technology and the ongoing shift towards minimally invasive procedures. The implications for the market are significant. As private equity firms inject capital into medical device companies, there is potential for accelerated innovation and development of new products. This influx of funding can enhance competition within the industry, leading to improved patient outcomes and potentially lowering costs in the long term. However, it also raises concerns about the sustainability of such investments, particularly if firms prioritize short-term gains over long-term viability. Yang emphasized the importance of strategic partnerships between private equity firms and medical device manufacturers to navigate regulatory challenges and market dynamics effectively. As this trend continues, stakeholders across the healthcare spectrum will need to monitor the evolving landscape, as the intersection of private equity and medical devices could reshape the future of healthcare delivery.

• Wearable Bioelectronic Skin Patches Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Sep 2, 2026

  The global wearable bioelectronic skin patches market is on a significant growth trajectory, projected to reach approximately USD 6.15 billion by 2030, with a compound annual growth rate (CAGR) of 22.3% from 2024. This surge is driven by increasing clinical adoption of advanced monitoring solutions, particularly single-lead ambulatory ECG patch monitors, which are becoming essential in the detection and management of conditions such as atrial fibrillation. The demand for non-invasive, real-time health monitoring technologies is further propelling market expansion, as healthcare providers seek efficient ways to enhance patient care. Strategic opportunities within the industry are emerging as companies invest in innovative technologies, including advanced sensors and biocompatible materials. However, the high costs associated with research, development, and manufacturing pose challenges for market players. As competition intensifies, firms will need to balance quality and affordability to capture market share effectively. The anticipated growth in this sector not only reflects a shift towards personalized healthcare solutions but also highlights the potential for wearable technology to transform patient monitoring and management practices across various healthcare settings.

• Self-Expanding Stents Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Aug 28, 2026

  The global self-expanding stents market is poised for significant growth, projected to increase from $4.51 billion in 2025 to $8.51 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.2%. This growth is driven by advancements in vascular intervention technologies, particularly the rising adoption of nitinol-based stents and a shift towards minimally invasive procedures. The expanding applications of self-expanding stents in peripheral interventions and the development of drug-compatible platforms are also key factors contributing to this upward trajectory. Emerging markets in the Asia Pacific region present substantial opportunities for market expansion, as healthcare systems increasingly recognize the benefits of self-expanding stents. The market dynamics in these regions are characterized by a growing demand for innovative medical devices that enhance patient outcomes and reduce recovery times. As healthcare providers seek to sustain long-term vessel openness, the emphasis on effective stent technologies is likely to intensify, further driving market growth. Overall, the self-expanding stents market is not only expanding in size but also evolving in its technological offerings, which could lead to increased competition among manufacturers. Companies that strategically position themselves to capitalize on these trends, particularly in emerging markets, may find lucrative opportunities in the coming years.

• Medtech M&A: choosing between private equity and strategic buyers
  Private Equity · Aug 27, 2026

  The medical technology (medtech) sector is experiencing a surge in mergers and acquisitions (M&A), with companies weighing the benefits of engaging private equity firms versus strategic buyers. Private equity firms are often drawn to medtech for their potential for high returns, leveraging financial engineering and operational improvements to enhance value. Conversely, strategic buyers, typically larger medtech companies, may offer synergies that can lead to accelerated growth and market expansion. As the landscape evolves, companies must consider their long-term goals when choosing between these two types of buyers. Private equity can provide the necessary capital and expertise to scale operations quickly, but may also impose a shorter investment horizon that prioritizes rapid returns. Strategic buyers, on the other hand, may be more patient and focused on integrating new technologies into their existing portfolios, potentially leading to more sustainable growth. Market implications are significant as the choice between these buyers can influence valuation metrics and deal structures. A preference for private equity could lead to increased competition for assets, driving up prices, while a strategic acquisition approach might foster a more collaborative environment, emphasizing innovation and product development. As the medtech sector continues to grow, understanding these dynamics will be crucial for stakeholders navigating this complex landscape.

• Platelet Aggregation Devices Market Outlook Signals Expansion To $2.93 Billion Through 2030
  Market Outlook · Aug 24, 2026

  The platelet aggregation devices market is poised for significant growth, with projections indicating an expansion from $1.04 billion in 2025 to approximately $2.93 billion by 2030. This represents a remarkable compound annual growth rate (CAGR) of 25.4% over the next several years. The surge in market value is attributed to increasing demand for advanced diagnostic tools in cardiovascular diseases, as well as rising awareness regarding the importance of platelet function testing in various medical settings. Market analysts anticipate that innovations in technology and product development will further drive this expansion. As healthcare providers increasingly adopt point-of-care testing and personalized medicine approaches, the need for efficient and accurate platelet aggregation devices will become more pronounced. This trend is expected to attract investments from both established players and new entrants in the medical device sector, potentially leading to heightened competition and advancements in product offerings. The implications for investors and stakeholders in the healthcare market are significant. With a robust growth trajectory forecasted, companies operating in this space may see enhanced revenue opportunities and improved market positioning. However, the rapid pace of innovation also necessitates that firms remain agile and responsive to evolving regulatory standards and technological advancements to maintain their competitive edge.

• Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
  Yahoo Finance · Aug 23, 2026

  Abbott Laboratories (NYSE: ABT) has recently reported strong fiscal Q2 2026 results, surpassing quarterly estimates and raising its annual profit forecast. The company's performance has been bolstered by robust demand for its cancer diagnostics and medical devices, signaling a solid recovery trajectory as healthcare markets rebound. This growth is particularly noteworthy given the broader context of the healthcare sector, which has been navigating challenges post-pandemic. In contrast, Thermo Fisher Scientific (NYSE: TMO) offers a diversified portfolio that spans various segments of the life sciences and diagnostics markets. While it may not exhibit the same immediate recovery potential as Abbott, Thermo Fisher's strength lies in its ability to provide stability through its wide-ranging operations. Investors must weigh the benefits of Abbott's focused growth strategy against Thermo Fisher's diversified approach, which may mitigate risks associated with sector volatility. Market implications suggest that investors leaning towards Abbott may be betting on a swift recovery in specific healthcare niches, particularly oncology, while those favoring Thermo Fisher might prioritize long-term stability and resilience against market fluctuations. As both companies continue to navigate evolving industry dynamics, the choice between diversification and recovery will ultimately depend on individual investor risk tolerance and market outlook.

• Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?
  Yahoo Finance · Aug 23, 2026

  Thermo Fisher Scientific and Intuitive Surgical, both leaders in the healthcare sector, are currently under scrutiny as investors evaluate their respective valuations amid strong quarterly performances. Thermo Fisher has positioned itself as a key player in the life sciences industry, with its growth increasingly tied to ongoing investments in research and development. Meanwhile, Intuitive Surgical, known for its robotic surgical systems, reported a significant surge in Q2 2026, showcasing its competitive advantages and a robust recurring revenue model. Despite their strong results, market reactions have diverged sharply. While Abbott Laboratories raised its annual profit outlook following a solid quarter, Intuitive Surgical's elevated valuation has led analysts to adopt a more cautious stance, rating it as a "Hold." Investors are now questioning the sustainability of Intuitive Surgical's growth trajectory, particularly in light of recent earnings that may not fully align with lofty expectations. This skepticism could impact the stock's performance in the near term, as market participants weigh the potential for future growth against its current price. As the healthcare sector continues to evolve, the contrasting market responses to Thermo Fisher and Intuitive Surgical highlight the complexities of valuing premium stocks. Investors must consider not only the companies' financial metrics but also the broader industry trends and the potential for innovation that could drive long-term growth. The outcome of this evaluation will be critical in determining which stock justifies its premium valuation in an increasingly competitive landscape.

• NutraCast: ‘It can be terrifying’: Tariffs, freight and geopolitics are squeezing the supplement supply chain
  Geopolitics · Aug 21, 2026

  The global supplement supply chain is facing unprecedented challenges due to a confluence of tariffs, rising freight costs, and geopolitical tensions. Industry experts warn that these factors are creating a "terrifying" environment for manufacturers and retailers alike, as they struggle to maintain inventory levels and manage costs. Tariffs imposed on raw materials and finished goods have significantly increased production expenses, while disruptions in shipping routes have led to delays and inflated freight charges. As companies grapple with these supply chain constraints, the implications for the supplement market are profound. Higher costs are likely to be passed on to consumers, potentially leading to reduced demand as price sensitivity increases. Additionally, the uncertainty surrounding international trade policies and geopolitical relations may compel businesses to rethink their sourcing strategies, potentially favoring domestic suppliers over foreign ones. This shift could reshape the landscape of the supplement industry, with long-term effects on pricing, availability, and market competition.

• Ocular Implants Market Outlook Signals Expansion To $27.68 Billion Through 2030
  Market Outlook · Aug 20, 2026

  The ocular implants market is projected to experience significant growth, reaching an estimated value of $27.68 billion by 2030, according to a recent analysis by Market Outlook. This expansion is driven by increasing prevalence of eye disorders, advancements in technology, and a growing aging population that demands innovative solutions for vision correction and enhancement. Key segments within the market include intraocular lenses, glaucoma implants, and retinal implants, each contributing to the overall growth trajectory. Market dynamics indicate that the rise in diabetic retinopathy and cataract cases, coupled with a surge in awareness regarding eye health, are pivotal factors propelling demand for ocular implants. Additionally, technological advancements, such as minimally invasive surgical techniques and the development of smart implants, are expected to further enhance patient outcomes and drive market penetration. As the market expands, stakeholders, including manufacturers and healthcare providers, will need to adapt to evolving consumer needs and regulatory environments. Investors may find opportunities in companies that are at the forefront of innovation in ocular health, as the demand for effective and efficient treatment options continues to rise. Overall, the ocular implants market is poised for robust growth, reflecting broader trends in healthcare and technology integration.

• Ophthalmic Medical Lasers Market Outlook Signals Expansion To $1.88 Billion Through 2030
  Market Outlook · Aug 20, 2026

  The ophthalmic medical lasers market is projected to experience significant growth, reaching an estimated value of $1.88 billion by 2030. This expansion is driven by increasing prevalence of eye disorders, advancements in laser technology, and a growing geriatric population that is more susceptible to conditions such as cataracts and glaucoma. The market is expected to benefit from innovations in laser procedures that enhance precision and reduce recovery times, making treatments more appealing to both patients and healthcare providers. Key players in the market are likely to invest in research and development to introduce new products and improve existing technologies. This competitive landscape may lead to strategic partnerships and mergers, further driving market growth. Additionally, the rising demand for minimally invasive surgical options is expected to bolster the adoption of ophthalmic lasers, as they offer effective solutions with lower risks and quicker recovery periods compared to traditional surgical methods. As the market evolves, stakeholders should closely monitor regulatory changes and reimbursement policies, which can significantly impact market dynamics. With the anticipated growth in the ophthalmic medical lasers sector, investors may find opportunities in companies that are well-positioned to capitalize on these trends, particularly those focused on innovation and patient-centric solutions.

All 21 articles in the app →

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen
• BMYBristol Myers Squibb